Search Results - "Aulitzky, W"

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network by Mross, K, Dittrich, C, Aulitzky, W E, Strumberg, D, Schutte, J, Schmid, R M, Hollerbach, S, Merger, M, Munzert, G, Fleischer, F, Scheulen, M E

“…Background: BI 2536, a novel Polo-like kinase 1 inhibitor, was assessed in patients with unresectable advanced exocrine adenocarcinoma of the pancreas…”
Get full text

RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38 by Weilbacher, A, Gutekunst, M, Oren, M, Aulitzky, W E, van der Kuip, H

“…Significant advances have been made in the development of small molecules blocking the p53/MDM2 interaction. The Mdm2 inhibitor Nutlin-3 is restricted to…”
Get full text

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV by Bergmann, L, Maute, L, Heil, G, Rüssel, J, Weidmann, E, Köberle, D, Fuxius, S, Weigang-Köhler, K, Aulitzky, W E, Wörmann, B, Hartung, G, Moritz, B, Edler, L, Burkholder, I, Scheulen, M E, Richly, H

“…Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumours and is still associated with a poor prognosis in advanced disease. To…”
Get full text

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma by METZGEROTH, G, WALZ, C, MÜLLER, M. C, BENEKE, H, MÜLLER, L, DEL VALLE, F, AULITZKY, W. E, WITTKOWSKY, G, SCHMITZ, N, SCHULTE, C, MULLER-HERMELINK, K, HODGES, E, SCORE, J, WHITTAKER, S. J, DIECKER, F, DÖHNER, H, SCHULD, P, HEHLMANN, R, HOCHHAUS, A, CROSS, N. C. P, REITER, A, SIEBERT, R, SCHNITTGER, S, HAFERLACH, C, POPP, H, HAFERLACH, T, ERBEN, P, MIX, J

“…The FIP1L1-PDGFRA fusion gene has been described in patients with eosinophilia-associated myeloproliferative disorders (Eos-MPD). Here, we report on seven…”
Get full text

Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles’ heel in mantle cell lymphoma by Dengler, M A, Weilbacher, A, Gutekunst, M, Staiger, A M, Vöhringer, M C, Horn, H, Ott, G, Aulitzky, W E, van der Kuip, H

“…Mantle cell lymphoma (MCL) is an aggressive lymphoid neoplasm with transient response to conventional chemotherapy. We here investigated the role of the Bcl-2…”
Get full text

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations by Heidrich, K, Thiede, C, Schäfer-Eckart, K, Schmitz, N, Aulitzky, W E, Krämer, A, Rösler, W, Hänel, M, Einsele, H, Baldus, C D, Trappe, R U, Stölzel, F, Middeke, J M, Röllig, C, Taube, F, Kramer, M, Serve, H, Berdel, W E, Ehninger, G, Bornhäuser, M, Schetelig, J

“…The value of allogeneic hematopoietic cell transplantation (alloHCT) as postremission treatment is not well defined for patients with intermediate-risk acute…”
Get full text

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial by Schetelig, J, Schaich, M, Schäfer-Eckart, K, Hänel, M, Aulitzky, W E, Einsele, H, Schmitz, N, Rösler, W, Stelljes, M, Baldus, C D, Ho, A D, Neubauer, A, Serve, H, Mayer, J, Berdel, W E, Mohr, B, Oelschlägel, U, Parmentier, S, Röllig, C, Kramer, M, Platzbecker, U, Illmer, T, Thiede, C, Bornhäuser, M, Ehninger, G

“…The optimal timing of allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML) is controversial. We report on 1179 patients…”
Get full text

Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial by Stölzel, F, Pfirrmann, M, Aulitzky, W E, Kaufmann, M, Bodenstein, H, Bornhäuser, M, Röllig, C, Kramer, M, Mohr, B, Oelschlägel, U, Schmitz, N, Soucek, S, Thiede, C, Ehninger, G, Schaich, M

“…Patients with secondary acute myeloid leukemia (sAML) are generally thought to have a poor prognosis. As there are no prognostic risk stratification models for…”
Get full text

Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML—long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL) by Thiel, A., Schetelig, J., Pönisch, W., Schäfer-Eckart, K., Aulitzky, W., Peter, N., Schulze, A., Maschmeyer, G., Neugebauer, S., Herbst, R., Hänel, A., Morgner, A., Kroschinsky, F., Bornhäuser, M., Lange, T., Wilhelm, M., Niederwieser, D., Ehninger, G., Fiedler, F., Hänel, M.

“…For patients with primary refractory or relapsed acute myeloid leukemia (AML), no treatment of choice has until now been defined to date. Cytarabine (Ara-C) is…”
Get full text

Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells by Fanta, S, Sonnenberg, M, Skorta, I, Duyster, J, Miething, C, Aulitzky, W E, van der Kuip, H

“…Imatinib inhibits the kinase activity of Bcr-Abl and is currently the most effective drug for treatment of chronic myeloid leukemia (CML). Imatinib also blocks…”
Get full text

Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL) by Betticher, DC, Martinelli, G, Radford, JA, Kaufmann, M, Dyer, MJS, Kaiser, U, Aulitzky, WE, Beck, J, von Rohr, A, Kovascovics, T, Cogliatti, SB, Cina, S, Maibach, R, Cerny, T, Linch, DC

“…Introduction: Sequential high dose (SHiDo) chemotherapy with stem cell support has been shown to prolong the event-free survival in patients with diffuse large…”
Get full text

PO-303 Modified P53 functionality in cancer-associated fibroblasts promotes cancer growth by Arundkar, SC, Furth, N, Elisha, Y, Nataraj, N, Kuip, HVD, Aulitzky, W, Ulitsky, I, Geiger, B, Oren, M

“…Introductionp53 is a seminal tumour suppressor protein, acting as a major barrier against cancer. So far, p53 research has focused primarily on its…”
Get full text

Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines by Jonuleit, Tarja, van der Kuip, Heiko, Miething, Cornelius, Michels, Heike, Hallek, Michael, Duyster, Justus, Aulitzky, Walter E.

“…Chronic myeloid leukemia (CML) is a malignant stem cell disease characterized by an expansion of myeloid progenitor cells expressing the constitutively…”
Get full text

Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study by Paulussen, M., Ahrens, S., Lehnert, M., Taeger, D., Hense, H. W., Wagner, A., Dunst, J., Harms, D., Reiter, A., Henze, G., Niemeyer, C., Göbel, U., Kremens, B., Fölsch, U. R., Aulitzky, W. E., A.Voûte, P., Zoubek, A., Jürgens, H.

“…Summary Background Ewing tumor treatment involves high cumulative doses of alkylating agents and topoisomerase inhibitors, drugs capable of inducing second…”
Get full text

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C by MÜLLER, M. C, GATTERMANN, N, KRAUSE, S. W, NERL, C, SAYER, H. G, OTTMANN, O. G, WALLER, C, AULITZKY, W, LE COUTRE, P, FREUND, M, MERX, K, PASCHKA, P, LAHAYE, T, KÖNIG, H, KREIL, S, BERGER, U, GSCHAIDMEIER, H, HEHLMANN, R, HOCHHAUS, A, DEININGER, M. W. N, BERNDT, A, FRUEHAUF, S, NEUHAUER, A, FISCHER, T, HOSSFELD, D. K, SCHNELLER, F

“…We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with chronic myelogenous leukemia (CML) in early chronic phase, randomized to…”
Get full text

Heart failure resulting from giant left atrial synovial sarcoma metastasis by Winkler, B, Grapow, M, Seeberger, M, Matt, P, Aulitzky, W, Eckstein, F

“…Synovial sarcoma metastasis affecting the heart and infiltrating the mitral valve is a very rare pathology. We report the case of a 44-year-old male treated…”
Get more information

Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation by KOLBE, K, DOMKIN, D, DERIGS, H. G, BHAKDI, S, HUBER, C, AULITZKY, W. E

“…Type, severity and incidence of infection during the neutropenic period after peripheral blood stem cell transplantation (PBSCT) for treatment of malignant…”
Get full text

Successful antiviral treatment for fulminant reactivated hepatitis B after autologous stem cell transplantation and prophylaxis during subsequent allogeneic stem cell transplantation by HENKES, M, MARTIN, S, EINSELE, H, AULITZKY, W. E

“…The risk of severe hepatic damage due to reactivation of hepatitis B virus (HBV) infection after intensive myelosuppressive chemotherapy is well known. Two of…”
Get full text

Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death by Moehring, A, Wohlbold, L, Aulitzky, W E, van der Kuip, H

“…Imatinib targets Bcr-Abl, the causative event of chronic myelogenous leukemia (CML), and addresses leukemic cells to growth arrest and cell death. The exact…”
Get full text

Identification of the NO synthase isoforms expressed in human neutrophil granulocytes, megakaryocytes and platelets by Wallerath, T, Gath, I, Aulitzky, W E, Pollock, J S, Kleinert, H, Förstermann, U

“…Using Western blot and fluorescent immunocytochemistry, NOS III (or ecNOS) and NOS II (or iNOS), but no NOS I (or ncNOS), were identified in preparations of…”
Get more information